Abbott’s Lake County Plant Gets FDA Nod; Prism Squares Up For U.S. Debut
This article was originally published in The Gray Sheet
Executive Summary
Abbott Labs will begin U.S. commercialization of its Prism, Architect and AxSYM full diagnostic assay menus over the next 12 months, following FDA's decision to end a four-year prohibition of product sales
You may also be interested in...
Abbott’s Recommitment To Core Diagnostics Is Rewarded By Strong Returns
Abbott has a newfound loyalty to its long-struggling core diagnostics business, which the company was at the brink of unloading just last year, and the division has responded with a dramatic turnaround
Abbott’s Recommitment To Core Diagnostics Is Rewarded By Strong Returns
Abbott has a newfound loyalty to its long-struggling core diagnostics business, which the company was at the brink of unloading just last year, and the division has responded with a dramatic turnaround
Abbott Diagnostics Quality System Violations Require Outside Audit By August
Abbott's pending sale of its diagnostics business to GE will not be affected by an FDA warning letter citing quality control problems at its Irving, Texas, plant, the company claims